Bevers, Nanja C. http://orcid.org/0000-0003-3646-5670
Keizer, Ron J.
Wong, Dennis R.
Aliu, Arta
Pierik, Marieke J.
Derijks, Luc J. J.
van Rheenen, Patrick F.
Article History
Accepted: 4 February 2024
First Online: 15 March 2024
Declarations
:
: No funding was received for the preparation of this article.
: Ron Keizer is an employee and stockholder of Insight RX, a company developing clinical decision software. Marieke J. Pierik reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZONMW (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from AbbVie, non-financial support from Ferring, non-financial support from Immunodiagnostics, and non-financial support from MSD, all outside the submitted work. Nanja Bevers, D.R. Wong, Arta Aliu, Luc J.J. Derijks and Patrick F. van Rheenen have no conflicts of interest that are directly relevant to the content of this article.
: This study was approved by the Medical Research Ethics Committee of both Zuyderland Medical Center and Maastricht University Medical Center (resp. approval number METCZ20220045 and METC 2022-3300).
: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
: NB, LD and PR contributed to the study concept and design. RK contributed to the statistical analysis. NB had full access to the data in the trial and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the acquisition, analysis or interpretation of the data. NB, LD and MP contributed to the drafting of the manuscript. All authors contributed to critical revision of the manuscript and provided important intellectual content. All authors approved the final version of this manuscript.